Reply to “Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19”

Baricitinib or imatinib in hospitalized COVID‐19 patients: Results from COVINIB, an exploratory randomized clinical trial

(2023) Alejandro Morales‐Ortega et al.   JOURNAL OF MEDICAL VIROLOGY

Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial

(2023) Stéphane Zuily et al.   EClinicalMedicine

Long-term clinical outcomes of COVID-19 patients treated with imatinib

(2022) Erik Duijvelaar et al.   Lancet Respiratory Medicine

Early antithrombotic therapy for another highly lethal viral pneumonia pandemic

(2022) Xiaoming Wu et al.   CLINICAL MICROBIOLOGY AND INFECTION

Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

(2021) Barry Dixon et al.   Lancet Respiratory Medicine

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

(2021)   NEW ENGLAND JOURNAL OF MEDICINE

The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials

(2021) Chia Siang Kow et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

(2021) Michelle Sholzberg et al.   BMJ-British Medical Journal